June 29, 2023 5:12pm

How many times am I right as sector dives as just one (1) trading session remains in 1H/23

Pre-open Indications: 7 Hits and 0 Miss

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed! Framing the main takeaway … pricing, volume and machine trading creates volatility and liquidity!

 

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +269.76 points (-0.80%), the S&P closed UP +19.58 points (+0.45%) while the Nasdaq closed DOWN -0.42 points (-0.00%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes were mixed as the Dow and S&P jumped while the Nasdaq declined.

“A slate of positive economic data signaled economic resilience despite looming recession fears. That included a large upward revision in first-quarter GDP and a drop in weekly jobless claims to the lowest level since May.” <CNBC>

Economic Data Docket: A surprise drop in initial jobless claims and a sharp upward revision in first-quarter GDP underscored U.S. economic resilience and further cemented the likelihood that the Fed will raise interest rates at least once, and maybe twice more, this year. <Reuters>

  • A sharp upward revision to Q2 GDP and a fall in jobless claims echoed recent releases reflecting strength in the economy, seen as providing scope for the Fed to keep raising rates.

 

Thursday (6/29) … RegMed Investors’ (RMi) pre-open: “willing to stay or sell into strength and make with a profit and come back another session. Momentum-driven sector equities are still at risk.” … https://www.regmedinvestors.com/articles/13024

 

Pre-open Indications: 7 Hits < Blueprint Medicine (BPMC +$1.28), CRISPR Therapeutics (CRSP -$0.14), Ionis Pharmaceuticals (IONS +$0.26), Intellia Therapeutics (NTLA -$1.25), Voyager Therapeutics (VYGR -$0.37), BioLife Solutions (BLFS +$0.oo)> and 0 Miss

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Thursday’s advance/decline line opened negative at 13 up/ 20 down and 2 flats, stayed negative with 11 up/ 20 down and 4 flats at the mid-day, ending with a negative close of 14 incliners, 17 decliners and 4 flats

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB was down -0.24% and the XBI was down -1.62%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +0.11 point or +0.82% at 13.54

 

Closing Down (10 of 17):

  • Alnylam Pharmaceuticals (ALNY -$5.50 after Wednesday’s +$7.76, Tuesday’s -$2.55 and Monday’s -$1.34),
  • Ultragenyx (RARE -$1.36 after Wednesday’s -$0.54, Tuesday’s -$0.07 and Monday’s -$1.58),
  • Beam Therapeutics (BEAM -$1.27 after Wednesday’s +$1.06),
  • Intellia Therapeutics (NTLA -$1.25 after Wednesday’s +$1.35, Tuesday’s -$1.08 and Monday’s +$0.90),
  • Verve Therapeutics (VERV -$0.63 after Wednesday’s +$0.70, Tuesday’s +$0.69 and Monday’s -$0.45),
  • Regenxbio (RGNX -$0.56 after Wednesday’s +$0.71, Tuesday’s +$1.27 and Monday’s -$0.48),
  • Voyager therapeutics (VYGR -$0.37),
  • Editas Medicine (EDIT -$0.25 after Wednesday’s +$0.34),
  • Prime Medicine (PRMC-$0.17),
  • bluebird bio (BLUE -$0.17),

Flat (4):

  • Bellicum Pharmaceuticals (BLCM)
  • BioLife Solutions (BLFS)
  • Brainstorm Cell Therapeutics (BCLI)
  • Biostage (OTCQB: BSTG)

Closing Up (10 of 14):

  • Vericel (VCEL +$1.66 after Wednesday’s -$0.65, Tuesday’s +$0.86 and Monday’s +$0.02),
  • Blueprint Medicine (BLMC +$1.28 after Wednesday’s +$2.10, Tuesday’s +$0.27 and Monday’s -$1.10),
  • Ionis Pharmaceuticals (IONS +$0.26 after Wednesday’s +$1.49, Tuesday’s +$0.26 and Monday’s -$0.54),
  • Mesoblast (MESO +$0.14),
  • Sage Therapeutics (SAGE +$0.13 after Wednesday’s -$0.21, Tuesday’s -$0.88 and Monday’s -$1.83),
  • Adverum Biotechnologies (ADVM +$0.06),
  • AxoGen (AXGN +$0.05 after Wednesday’s -$0.09 after Tuesday’s +$0.10),
  • Sangamo Therapeutics (SGMO +$0.05),
  • Homology Medicine (FIXX +$0.04),
  • MiMedx (MDXG +$0.04),

 

Q2/23 – June

  • Thursday closed negative with 14 incliners, 17 decliners and 4 flats

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

The title states the story of the day.

The coming issue is the end of Q2 next week; yet, Q reporting is weeks if not a month away.

 

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Reiterating, there was VALUE out there as electronic trading and algorithms stated their claim to the upside on Tuesday, it’s STILL about playing or betting and timing of the sector.

 

Unresolved issues --- political investigation of the White House and the Bidens, future rate increases, escalation of the Ukraine war, a Russia uncertainty after a on mercenary versus Russia fight and the major issue - recession - US and global could freezing investors' mood.

A long holiday is upon us, it will be good to get this market and sector out-of-mind and yet another birthday (7/2)!

 

The top three (3) performing in the session:

·         Thursday: Vericel (VCEL), Blueprint Medicine (BPMC) – again and Ionis Pharmaceuticals (IONS) - again

·         Wednesday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and Ionis Pharmaceuticals (IONS) 

·         Tuesday: Regenxbio (RGNX), Vericel (VCEL) – again, and Verve Therapeutics (VERV)

·         Monday: Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)

While The worst three (3) in the session:

·         Thursday: Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE) and Beam Therapeutics (BEAM)

·         Wednesday: Vericel (VCEL), Ultragenyx (RARE) and BioLife Solutions (BLFS)

·         Tuesday: Alnylam Pharmaceuticals (ALNY), Intellia Therapeutics (NTLA) and Generation Bio (GBIO)

·         Monday: Sage Therapeutics (SAGE), and Alnylam Pharmaceuticals (ALNY) - again

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

Biostage (OTCQB: BSTG) … so many issues from the past as many of those “miscreant management” members are still employed!

Thursday closed FLAT with 0 shares traded after Wednesday closed up +$0.02 with 425 shares traded, Tuesday closed down-$0.05 with 624 shares traded, Monday closed flat with 0 shares traded, Friday closed down -$0.19 with 2,673 shares traded and last Thursday closed down -$0.40 with 5,400 <3-month average = 850 shares>

·         Question: Review the number of shares traded on a weekly and monthly basis … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!

·         OTCQB: BSTG is holding their annual meeting on 7/19, to vote the Beijing, China designated directors …??? Certainly NOT a US company ANYMORE!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.